Piper Jaffray Upgrades Achillion Pharmaceuticals To Overweight

Analysts at Piper Jaffray upgraded Achillion Pharmaceuticals

from Neutral to Overweight. The target price for Achillion Pharmaceuticals has been raised from $5.00 to $10.00. Achillion Pharmaceuticals shares have surged 14.29% over the past 52 weeks, while the S&P 500 index has gained 14.20% in the same period. Achillion Pharmaceuticals' shares surged 7.74% to $7.93 in pre-market trading.